<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="systematic-review"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012609</article-id><article-id pub-id-type="pmc">PMC11860874</article-id><article-id pub-id-type="doi">10.3389/fcimb.2025.1441185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy and safety of <italic>Saccharomyces boulardii</italic> as an adjuvant therapy for the eradication of <italic>Helicobacter pylori</italic>: a meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Manning</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2753117"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xie</surname><given-names>Ying</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/924251"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Department of Gastroenterology, Shengjing Hospital of China Medical University</institution>, <addr-line>Shenyang, Liaoning</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Hamid Reza Nouri, National Jewish Health (United States), United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Norma Velazquez-Guadarrama, Federico G&#x000f3;mez Children&#x02019;s Hospital, Mexico</p><p>Raluca Simona Costache, Carol Davila University of Medicine and Pharmacy, Romania</p></fn><corresp id="fn001">*Correspondence: Ying Xie, <email xlink:href="mailto:sheana407@163.com">sheana407@163.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>1441185</elocation-id><history>
<date date-type="received"><day>30</day><month>5</month><year>2024</year></date>
<date date-type="accepted"><day>15</day><month>1</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 Li and Xie</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Li and Xie</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>
<italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) is highly prevalent worldwide and is closely associated with many gastric conditions. Current methods for eradicating <italic>H. pylori</italic> include triple or quadruple therapy, including antibiotics, proton pump inhibitors, and bismuth agents; however, with antibiotic abuse and increased drug resistance rates, the effectiveness of traditional methods is gradually decreasing, with many adverse effects such as abdominal pain, diarrhea, and intolerance. In recent years, there has been controversy regarding whether adding <italic>Saccharomyces boulardii</italic> (<italic>S. boulardii</italic>) to traditional therapies is beneficial for eradicating <italic>H. pylori</italic>.</p></sec><sec><title>Aim</title><p>To evaluate the efficacy and safety of <italic>S. boulardii</italic> as an adjuvant therapy for the eradication of <italic>H. pylori</italic>.</p></sec><sec><title>Methods</title><p>We systematically searched the PubMed and Web of Science databases from January 2002 to January 2023. The primary outcome was the <italic>H. pylori</italic> eradication rate. The secondary outcomes included total adverse effects, abdominal pain, diarrhea, bloating, constipation, nausea, vomiting, taste disorders, and other adverse reactions. We evaluated the included studies for publication bias and heterogeneity. Fixed- and random-effects models were used for studies without and with heterogeneity, respectively, to calculate the risk ratios (RRs) and conduct sensitivity and subgroup analyses.</p></sec><sec><title>Results</title><p>Nineteen studies comprising 5,036 cases of <italic>H. pylori</italic> infection were included in this meta-analysis. The addition of <italic>S. boulardii</italic> to traditional therapy significantly improved the <italic>H. pylori</italic> eradication rate [RR=1.11, 95% confidence interval (CI): 1.08&#x02013;1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37&#x02013;0.66), diarrhea (RR=0.36, 95% CI: 0.26&#x02013;0.48), abdominal distension (RR=0.49, 95% CI: 0.33&#x02013;0.72), constipation (RR=0.38, 95% CI: 0.26&#x02013;0.57), and nausea (RR=0.50, 95% CI: 0.37&#x02013;0.68). However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.</p></sec><sec><title>Conclusions</title><p>
<italic>S. boulardii</italic> supplementation in traditional eradication therapy significantly improves the <italic>H. pylori</italic> eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.</p></sec><sec><title>Systematic review registration</title><p>Prospero, identifier CRD42024549780.</p></sec></abstract><kwd-group><kwd><italic>Saccharomyces boulardii</italic></kwd><kwd><italic>Helicobacter pylori</italic></kwd><kwd>meta-analysis</kwd><kwd>eradication rate</kwd><kwd>adverse effects</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Doctoral Start-up Foundation of Liaoning Province (Contract No. 2022-BS-127).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="42"/><page-count count="10"/><word-count count="4244"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Intestinal Microbiome</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>
<italic>H. pylori</italic> is a Gram-negative bacterium that is closely associated with chronic gastritis, peptic ulcers, gastric cancer, and gastric mucosal tissue-related lymphoma. It is classified as a Class I carcinogen by the World Health Organization (<xref rid="B25" ref-type="bibr">Peek, 2013</xref>). Approximately 50% of people worldwide are infected with <italic>H. pylori</italic> (<xref rid="B21" ref-type="bibr">Mesquita et&#x000a0;al., 2022</xref>; <xref rid="B16" ref-type="bibr">Katelaris et&#x000a0;al., 2023</xref>), and the infection and recurrence rates in developing countries are higher than those in developed countries (<xref rid="B30" ref-type="bibr">Sun and Zhang, 2019</xref>). In China, the total prevalence rate is 44.2%, with an estimated 589 million people infected with <italic>H. pylori</italic> (<xref rid="B26" ref-type="bibr">Ren et&#x000a0;al., 2022</xref>).Currently, the mainstream method for eradicating <italic>H. pylori</italic> is triple or quadruple therapy, including antibiotics, proton pump inhibitors, and bismuth agents (<xref rid="B14" ref-type="bibr">Helicobacter pylori Study Group, C. S. o. G and Chinese Medical Association, 2022</xref>). The triple therapy proposed at the first Maastricht Conference, including PPI, clarithromycin and amoxicillin, is currently the most common therapy (<xref rid="B19" ref-type="bibr">Malfertheiner et&#x000a0;al., 2012</xref>).However, with the abuse of antibiotics and the increase in drug resistance rates, the effectiveness of this traditional method is gradually decreasing, with many adverse effects such as abdominal pain, diarrhea, aggravation of nausea or vomiting and intolerance (<xref rid="B10" ref-type="bibr">Flores-Trevi&#x000f1;o et&#x000a0;al., 2018</xref>).The consensus states that if the resistance rate of clarithromycin in a region is greater than 15%, the triple therapy of PPI, clarithromycin and amoxicillin should be abandoned and replaced with PPI, metronidazole and amoxicillin, or a quadruple therapy containing bismuth: bismuth, PPI, tetracycline and metronidazole. The consensus also mentioned that <italic>S. boulardii</italic> has a certain effect on improving <italic>H. pylori</italic> infection.</p><p>
<italic>S. boulardii</italic> is a yeast that has been isolated from the peel of tropical fruits and is commonly used to treat gastrointestinal diseases such as diarrhea (<xref rid="B17" ref-type="bibr">Ka&#x0017a;mierczak-Siedlecka et&#x000a0;al., 2020</xref>; <xref rid="B24" ref-type="bibr">Pais et&#x000a0;al., 2020</xref>). In recent years, domestic and international studies have shown that <italic>S. boulardii</italic> has a positive effect on the eradication of <italic>H. pylori</italic> (<xref rid="B31" ref-type="bibr">Szajewska et&#x000a0;al., 2015</xref>; <xref rid="B28" ref-type="bibr">Seddik et&#x000a0;al., 2019</xref>; <xref rid="B34" ref-type="bibr">Yang et&#x000a0;al., 2022</xref>). In 2017, Yang et&#x000a0;al. found that <italic>S. boulardii</italic> could inhibit the formation of gastric lymphatic follicles caused by <italic>H. pylori</italic> infection, thereby reducing the incidence of adverse effects (<xref rid="B18" ref-type="bibr">Lazo-V&#x000e9;lez et&#x000a0;al., 2018</xref>). Previous studies have also indicated that <italic>S. boulardii</italic> can directly destroy <italic>H. pylori</italic> cells, resulting in cell destruction and damage. It produces substances, such as short chain fatty acids, that inhibit <italic>H. pylori</italic> growth (<xref rid="B20" ref-type="bibr">McFarland, 2010</xref>).Moreover, although <italic>S. boulardii</italic> cannot completely eradicate <italic>H. pylori</italic>, it can reduce the colonization of <italic>H. pylori</italic> in the intestines of children (<xref rid="B23" ref-type="bibr">Namkin et&#x000a0;al., 2016</xref>). The possible mechanism for this is <italic>S. boulardii</italic>&#x02019;s expression of neuraminidase activity selective for &#x003b1;2,3-linked sialic acid, which can inhibit the adhesion of <italic>H. pylori</italic> to duodenal epithelial cells (<xref rid="B27" ref-type="bibr">Sakarya and Gunay, 2014</xref>). Also <italic>S. boulardii</italic> has been shown to stabilize the tight junction of gastric mucosal epithelial cells, stimulating SIgA response and strengthening the gastric mucosal barrier (<xref rid="B2" ref-type="bibr">Buts et&#x000a0;al., 1990</xref>; <xref rid="B8" ref-type="bibr">Dahan et&#x000a0;al., 2003</xref>).Moreover, some theories suggest that <italic>S. boulardii</italic> can reduce the abundance of antibiotic-resistance genes and reduce the unsatisfactory traditional treatment effects caused by antibiotic resistance (<xref rid="B5" ref-type="bibr">Cifuentes et&#x000a0;al., 2022</xref>). To further clarify the role of <italic>S. boulardii</italic> in the eradication of <italic>H. pylori</italic>, we conducted a retrospective meta-analysis of randomized controlled trials published between January 2002 and January 2023 and evaluated the impact of adding <italic>S. boulardii</italic> to traditional methods for the eradication of <italic>H. pylori</italic> infection.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2_1"><title>Data sources and literature search</title><p>We systematically searched the PubMed and Web of Science databases for literature published from January 2002 to January 2023, using the search terms &#x0201c;<italic>H. pylori</italic>&#x0201d; and &#x0201c;<italic>S. boulardii</italic>.&#x0201d; In total, 125 articles were detected.</p></sec><sec id="s2_2"><title>Study selection criteria</title><p>The inclusion criteria were as follows: (1) randomized controlled trials; (2) <italic>H. pylori</italic> infection patients positive for <italic>H. pylori</italic> antigens or with a positive 14C breath test; (3) a control group consisting of standard triple therapy, quadruple therapy, sequential therapy, or the addition of a placebo to the standard therapy; (4) experimental group treated with the addition of <italic>S. boulardii</italic> to the standard therapy; and (5) outcomes including the eradication rate of <italic>H. pylori</italic>, overall adverse effects, abdominal pain, diarrhea, bloating, nausea and vomiting. The exclusion criteria were as follows: (1) therapy consisting of a combination of <italic>S. boulardii</italic> and other non-<italic>S. boulardii</italic> probiotics; (2) animal experiments; (3) meta-analyses, reviews, and conference abstracts; (4) repetitive literature published in different publications; (5) non-randomized controlled trials; and (6) inability to obtain full text or incomplete data. Two reviewers independently screened the studies by reading the titles and abstracts and obtained the full texts of the relevant articles. Any differences were resolved by consensus.</p></sec><sec id="s2_3"><title>Data extraction</title><p>The following data were extracted from each eligible study: first author, year of publication, study location, patient age, number of participants, eradication protocol, <italic>S. boulardii</italic> protocol, and follow-up duration. Two reviewers independently extracted data from each selected study and any differences were resolved by consensus.</p></sec><sec id="s2_4"><title>Evidence quality and bias test</title><p>A Cochrane quality evaluation form (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>) was developed to evaluate the quality of the studies. Using the Egger test, we found that the selected studies had no publication bias, indicating that the conclusions of this study were accurate and reliable.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Cochrane Quality Evaluation Form. Studies were analyzed for a variety of bias using the tools in Review Manager software (Version 5.4).</p></caption><graphic xlink:href="fcimb-15-1441185-g001" position="float"/></fig></sec><sec id="s2_5"><title>Meta-analysis and statistical analysis</title><p>All statistical analyses were conducted using Review Manager software (version 5.4; Cochrane Collaboration, Oxford, UK), and the results were expressed as the risk ratio (RR) with a 95% confidence interval (CI). Statistical significance was set at P&#x0003c;0.05.</p><p>We used I<sup>2</sup> statistics to evaluate heterogeneity, with I<sup>2</sup> values of 0%&#x02013;25%, 26%&#x02013;50%, 51%&#x02013;75%, and &#x0003e;75% indicating no heterogeneity, low heterogeneity, medium heterogeneity, and high heterogeneity, respectively. For studies without heterogeneity, a fixed-effects model was used to calculate the RRs. In contrast, for studies with heterogeneity, a random-effects model was used to calculate the RRs, and sensitivity and subgroup analyses were performed.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Literature search process and results</title><p>A total of 149 studies published between January 2002 and January 2023 were included. After removing duplicate and unrelated records, 57 full-text articles were evaluated, of which 38 studies were excluded based on the selection criteria. Therefore, the final meta-analysis included 19 studies (<xref rid="B7" ref-type="bibr">Cremonini et&#x000a0;al., 2002</xref>; <xref rid="B9" ref-type="bibr">Duman et&#x000a0;al., 2005</xref>; <xref rid="B6" ref-type="bibr">Cindoruk et&#x000a0;al., 2007</xref>; <xref rid="B15" ref-type="bibr">Hurduc et&#x000a0;al., 2009</xref>; <xref rid="B29" ref-type="bibr">Song et&#x000a0;al., 2010</xref>; <xref rid="B41" ref-type="bibr">Zojaji et&#x000a0;al., 2013</xref>; <xref rid="B36" ref-type="bibr">Zhao et&#x000a0;al., 2014</xref>; <xref rid="B1" ref-type="bibr">Bin et&#x000a0;al., 2015</xref>; <xref rid="B31" ref-type="bibr">Szajewska et&#x000a0;al., 2015</xref>; <xref rid="B33" ref-type="bibr">Wang and Yu, 2015</xref>; <xref rid="B4" ref-type="bibr">Chotivitayatarakorn et&#x000a0;al., 2017</xref>; <xref rid="B39" ref-type="bibr">Zhu et&#x000a0;al., 2017</xref>; <xref rid="B40" ref-type="bibr">Zhu et&#x000a0;al., 2018</xref>; <xref rid="B12" ref-type="bibr">He et&#x000a0;al., 2019</xref>; <xref rid="B13" ref-type="bibr">He et&#x000a0;al., 2019</xref>; <xref rid="B28" ref-type="bibr">Seddik et&#x000a0;al., 2019</xref>; <xref rid="B3" ref-type="bibr">Chang et&#x000a0;al., 2020</xref>; <xref rid="B37" ref-type="bibr">Zhao et&#x000a0;al., 2021</xref>; <xref rid="B22" ref-type="bibr">Naghibzadeh et&#x000a0;al., 2022</xref>). A PRISMA flowchart of the study selection process is shown in <xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Flow Chart of Literature Screening. A flow diagram of articles retrieved and inclusion progress through the stage of meta-analysis.</p></caption><graphic xlink:href="fcimb-15-1441185-g002" position="float"/></fig></sec><sec id="s3_2"><title>Characteristics of the included studies</title><p>A total of 19 randomized controlled trials involving 5,036 patients (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>) were included, of which 9 were domestic studies and 10 were foreign studies; 15 were adult studies and 4 were child studies; and 13 used triple therapy, 5 used quadruple therapy, and 1 used sequential therapy. Moreover, regarding the duration of therapy, four studies used 7-day therapy, 13 studies used 14-day therapy, one study collected data on both 7-day and 14-day therapy, and one study used 10-day therapy.</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Basic characteristics of included study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">First author and year</th><th valign="middle" align="left" rowspan="1" colspan="1">Country</th><th valign="middle" align="left" rowspan="1" colspan="1">Publication</th><th valign="middle" align="left" rowspan="1" colspan="1">No. of patients</th><th valign="middle" align="left" rowspan="1" colspan="1">Patients</th><th valign="middle" align="left" rowspan="1" colspan="1">Eradication regimen</th><th valign="middle" align="left" rowspan="1" colspan="1">
<italic>S. boulardii</italic> regimen (dose, duration)</th><th valign="middle" align="left" rowspan="1" colspan="1">Follow&#x02010;up post&#x02010;treatment time</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Yang, G. B. 2022</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">497</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Rabeprazole 20mg bid,amoxicillin 1.0g bid,clarithromycin 0.5g bid,10d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">14d,44d</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Naghibzadeh, N. 2022</td><td valign="middle" align="left" rowspan="1" colspan="1">Iran</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">156</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Amoxicillin 1.0g bid,clarithromycin 0.5g bid,PPI 40mg bid,bismuth subcitrate 240mg bid,14d,PPI 40mg bid for another 14d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">7d,14d,21d,28d</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Zhao, Yuchong 2021</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">360</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Esomeprazole 20mg bid,amoxicillin 1.0g bid,clarithromycin 0.5g bid,bismuth potassium citrate 600mg bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w-12w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Chang, Y. W. 2020</td><td valign="middle" align="left" rowspan="1" colspan="1">Korea</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">183</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Pantoprazole 40mg bid,amoxicillin 1.0g bid,clarithromycin 0.5g bid,7d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g tid,4w</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Seddik, H. 2019</td><td valign="middle" align="left" rowspan="1" colspan="1">Morocco</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">199</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole 20mg bid, amoxicillin 1.0g bid for the first 5d, followed by omeprazole 20mg bid, clarithromycin 0.5g bid,metronidazole 0.5g bid for the remaining 5d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,10d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">He, Jin'e 2019</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">120</td><td valign="middle" align="left" rowspan="1" colspan="1">Children</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole 0.7~0.8mg/(kg.d),amoxicillin 50mg/(kg.d),clindamycin 20mg/(kg.d),14d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">He, C. X. 2019</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">300</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Pantoprazole 40mg bid,amoxicillin 1.0g bid ,furazolidone 100mg bid,bismuth potassium citrate 220mg bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Zhu, X. Y. 2018</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">360</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Bismuth potassium citrate 220mg bid, esomeprazole 10mg bid, amoxicillin 1.0g bid, furazolidone 100mg bid, 10 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Zhu, X. Y. 2017</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">240</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Bismuth potassium citrate 220mg bid, rabeprazole 10mg bid, amoxicillin 1.0g bid, furazolidone 100mg bid, 10 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14 d,28 d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Chotivitayatarakorn, Peranart 2017</td><td valign="middle" align="left" rowspan="1" colspan="1">Thailand</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">108</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Dexlansoprazole 60mg bid, moxifloxacin 400mg qd, clarithromycin 1.0g qd, 7d,14 d</td><td valign="middle" align="left" rowspan="1" colspan="1">282.5mg bid,7d,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Wang, Likun 2015</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">240</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Pantoprazole 40mg bid,amoxicillin 1.0g bid ,clarithromycin 0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">282.5mg bid,14d,21d,28d</td><td valign="middle" align="left" rowspan="1" colspan="1">1w,2w,3w,4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Bin, Zhang 2015</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">194</td><td valign="middle" align="left" rowspan="1" colspan="1">Children</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole (NR) , clarithromycin (NR) , amoxicillin (or metronidazole; NR) , 14 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Zhao, Hong-Mei 2014</td><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">240</td><td valign="middle" align="left" rowspan="1" colspan="1">Children</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole 0.7-0.8 mg/(kg.d) qd, amoxicillin 40 mg/(kg.d) tid, clarithromycin 15 mg/(kg.d) bid, 14 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Zojaji, Homayoun 2013</td><td valign="middle" align="left" rowspan="1" colspan="1">Iran</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">160</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole 20mg bid,amoxicillin 1.0g bid, clarithromycin 500mg bid, 14 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">8w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Song, M. J. 2010</td><td valign="middle" align="left" rowspan="1" colspan="1">Korea</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">991</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole 20mg bid, amoxicillin 1.0g bid, clarithromycin 500mg bid, 7 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g tid,28d</td><td valign="middle" align="left" rowspan="1" colspan="1">4w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hurduc, V. 2009</td><td valign="middle" align="left" rowspan="1" colspan="1">Romania</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">90</td><td valign="middle" align="left" rowspan="1" colspan="1">Children</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprozole or esomeprazole 0.5 mg/kg bid, 21d, clarothromycin 7.5 mg/kg bid, amoxicillin 25 mg/kg bid, 7&#x02010;10 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.25g bid,28d</td><td valign="middle" align="left" rowspan="1" colspan="1">4-6w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Cindoruk, M. 2007</td><td valign="middle" align="left" rowspan="1" colspan="1">Turkey</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">124</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Lansoprazole 30mg bid, amoxicillin 1.0g bid, clarithromycin 500mg bid, 14 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">6w</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Duman, D. G. 2005</td><td valign="middle" align="left" rowspan="1" colspan="1">Turkey</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">389</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Omeprazole 20mg bid, amoxicillin 1.0g bid, clarithromycin 500mg bid, placebo 250mg bid,14 d</td><td valign="middle" align="left" rowspan="1" colspan="1">0.5g bid,14d</td><td valign="middle" align="left" rowspan="1" colspan="1">15-45d</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Cremonini, F. 2002</td><td valign="middle" align="left" rowspan="1" colspan="1">Italy</td><td valign="middle" align="left" rowspan="1" colspan="1">Full paper</td><td valign="middle" align="center" rowspan="1" colspan="1">85</td><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="left" rowspan="1" colspan="1">Rabeprazole 20mg bid, clarithromycin 500mg bid, tinidazole 500mg bid, placebo 2 sachets/day, 7 d</td><td valign="middle" align="left" rowspan="1" colspan="1">5x10<sup>9</sup>/CFU bid, 14d</td><td valign="middle" align="left" rowspan="1" colspan="1">5-7w</td></tr></tbody></table><table-wrap-foot><fn><p>bid, twice daily; qd, once daily; d,day; w, week; CFU, colony&#x02010;forming units; NR, not reported; PPI, Proton Pump Inhibitors.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_3"><title>Primary outcome: <italic>H. pylori</italic> eradication rate</title><sec id="s3_3_1"><title>Eradication rate</title><p>Among the 19 included articles, 18 statistically analyzed the eradication rate of <italic>H. pylori</italic>. We performed ITT analysis on 18 articles (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>) and the results showed no heterogeneity (I<sup>2</sup> = 23%, P=0.18). Using a fixed-effects model, we found that the eradication rate was increased by 11% when using <italic>S. boulardii</italic> supplementation (RR=1.11, 95% Cl: 1.08&#x02013;1.15, P&#x0003c;0.0001), with no observed bias (Egger&#x02019;s test: P=0.068), proving that supplementation with <italic>S. boulardii</italic> can improve the eradication rate of the standard protocol.</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Forest plot of eradication rate. Forest plot analyzing the eradication rate of <italic>S. boulardii</italic> as an adjuvant therapy for <italic>H. pylori</italic>.</p></caption><graphic xlink:href="fcimb-15-1441185-g003" position="float"/></fig></sec><sec id="s3_3_2"><title>Layered analysis</title><p>Subgroup analysis stratified by patient age indicated that the eradication rate in children (RR=1.14, 95% CI: 1.05&#x02013;1.25, P=0.002) was 5% higher than that in adults (RR=1.09, 95% CI: 1.04&#x02013;1.14, P=0.0002).</p><p>Subgroup analysis stratified by study location revealed that the eradication rate in China (RR=1.12, 95% CI: 1.04&#x02013;1.19, P=0.001) was 2% higher than that in foreign countries (RR=1.10, 95% CI: 1.05&#x02013;1.15, P=0.0001).</p><p>Subgroup analysis stratified by the standard eradication protocol showed that the eradication rate with quadruple therapy (RR=1.12, 95% CI: 1.06&#x02013;1.19, P=0.0002) increased by 7% when compared with triple therapy (RR=1.05, 95% CI: 1.00&#x02013;1.11, P=0.04). Moreover, the eradication rate of sequential therapy increased by 3% when compared with quadruple therapy.</p><p>Subgroup analysis stratified by medication duration showed that there was no significant difference between the 7-day therapy (RR=1.09, 95% CI: 1.03&#x02013;1.17, P=0.006) and the 14-day therapy (RR=1.10, 95% CI: 1.04&#x02013;1.16, P=0.0007), with only a 1% difference. However, the addition of <italic>S. boulardii</italic> to the 7-day therapy did not increase the eradication rate at 4 weeks (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>).</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Layered analysis of eradication rate.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Subgroup</th><th valign="middle" align="center" rowspan="1" colspan="1">Number of Articles</th><th valign="middle" align="center" rowspan="1" colspan="1">Sample size</th><th valign="middle" align="center" rowspan="1" colspan="1">RR(95%)</th><th valign="middle" align="center" rowspan="1" colspan="1">P</th><th valign="middle" align="center" rowspan="1" colspan="1">I<sup>2</sup>(%)</th></tr></thead><tbody><tr><th valign="middle" colspan="6" align="left" rowspan="1">Stratified by age</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Children</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">492</td><td valign="middle" align="center" rowspan="1" colspan="1">1.14 (1.05,1.25)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Adults</td><td valign="middle" align="center" rowspan="1" colspan="1">14</td><td valign="middle" align="center" rowspan="1" colspan="1">3215</td><td valign="middle" align="center" rowspan="1" colspan="1">1.09 (1.04,1.14)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0002</td><td valign="middle" align="center" rowspan="1" colspan="1">37</td></tr><tr><th valign="middle" colspan="6" align="left" rowspan="1">Stratified by study location</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">China</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">2096</td><td valign="middle" align="center" rowspan="1" colspan="1">1.12 (1.04,1.19)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.001</td><td valign="middle" align="center" rowspan="1" colspan="1">51</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Foreign</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">1611</td><td valign="middle" align="center" rowspan="1" colspan="1">1.10 (1.05,1.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0001</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><th valign="middle" colspan="6" align="left" rowspan="1">Stratified according to the standard eradication protocol</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Triple therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">5</td><td valign="middle" align="center" rowspan="1" colspan="1">1232</td><td valign="middle" align="center" rowspan="1" colspan="1">1.05 (1.00,1.11)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.04</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Quadruple therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="center" rowspan="1" colspan="1">2276</td><td valign="middle" align="center" rowspan="1" colspan="1">1.12 (1.06,1.19)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0002</td><td valign="middle" align="center" rowspan="1" colspan="1">42</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Sequential treatment</td><td valign="middle" align="center" rowspan="1" colspan="1">1</td><td valign="middle" align="center" rowspan="1" colspan="1">199</td><td valign="middle" align="center" rowspan="1" colspan="1">1.15 (1.00,1.32)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.05</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><th valign="middle" colspan="6" align="left" rowspan="1">Stratified by medication course</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">7-day therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">5</td><td valign="middle" align="center" rowspan="1" colspan="1">970</td><td valign="middle" align="center" rowspan="1" colspan="1">1.09 (1.03,1.17)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.006</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">14-day therapy</td><td valign="middle" align="center" rowspan="1" colspan="1">13</td><td valign="middle" align="center" rowspan="1" colspan="1">2538</td><td valign="middle" align="center" rowspan="1" colspan="1">1.10 (1.04,1.16)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0007</td><td valign="middle" align="center" rowspan="1" colspan="1">44</td></tr></tbody></table><table-wrap-foot><fn><p>Subgroup analysis of the eradication rate of <italic>S. boulardii</italic> as an adjuvant therapy for <italic>H. pylori</italic>. RR, relative risk; P, probability.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3_4"><title>Secondary outcome: adverse effects</title><sec id="s3_4_1"><title>Total adverse effects</title><p>Among the 19 included articles, 9 analyzed the differences in overall adverse effects after the addition of <italic>S. boulardii</italic> (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>), and these studies showed high heterogeneity (I<sup>2</sup> = 79%, P&#x0003c;0.00001). In total, the overall adverse effects decreased by 51% (RR=0.49, 95% CI: 0.37&#x02013;0.66, P&#x0003c;0.00001) when using random effects combined with effect measures.</p><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Forest plot analyzing the total adverse effects of <italic>S. boulardii</italic> as an adjuvant therapy for <italic>H. pylori</italic>.</p></caption><graphic xlink:href="fcimb-15-1441185-g004" position="float"/></fig></sec></sec><sec id="s3_5"><title>Other adverse effects</title><sec id="s3_5_1"><title>Diarrhea</title><p>We performed a meta-analysis on 16 articles reporting the incidence of diarrhea. These studies had moderate heterogeneity (I<sup>2</sup> = 58%, P=0.002). Using random effects combined with effect measures, we found that the incidence of diarrhea decreased by 64% (RR=0.36, 95% CI: 0.26&#x02013;0.48, P&#x0003c;0.0001) with <italic>S. boulardii</italic> supplementation.</p></sec><sec id="s3_5_2"><title>Abdominal pain</title><p>A meta-analysis was conducted on nine articles reporting the incidence of abdominal pain, and we found that these studies had no heterogeneity (I<sup>2</sup> = 0%, P=0.79). Using a fixed-effects model, we found no significant difference in the incidence of abdominal pain between the <italic>S. boulardii</italic> and control groups (RR=0.78, P=0.10). Therefore, the addition of <italic>S. boulardii</italic> did not reduce the incidence of abdominal pain.</p></sec><sec id="s3_5_3"><title>Abdominal distension</title><p>We conducted a meta-analysis on seven articles with mild heterogeneity (I<sup>2</sup> = 43%, P=0.10) reporting the incidence of abdominal distension. Random effects were used to merge the effects, and we found that the abdominal distension rate decreased by 51% (RR=0.49, 95% CI: 0.33&#x02013;0.72, P=0.0004) with <italic>S. boulardii</italic> supplementation, without bias (Egger&#x02019;s test: P=0.994).</p></sec><sec id="s3_5_4"><title>Constipation</title><p>A meta-analysis was conducted on six articles reporting the incidence of constipation. These studies had no heterogeneity (I<sup>2</sup> = 0%, P=0.48). Therefore, we used a fixed-effects model and found that the addition of <italic>S. boulardii</italic> significantly reduced the incidence of constipation (RR=0.38, 95% CI: 0.26&#x02013;0.57, P&#x0003c;0.00001). The results were unbiased (Egger&#x02019;s test: P=0.973).</p></sec><sec id="s3_5_5"><title>Nausea</title><p>We performed a meta-analysis on 12 articles with mild heterogeneity (I<sup>2</sup> = 48%, P=0.03) reporting the incidence of nausea. Random effects were used to merge the effects, and we found that the nausea rate decreased by 50% (RR=0.50, 95%: 0.37&#x02013;0.68, P&#x0003c;0.00001) with <italic>S. boulardii</italic> supplementation. The results were statistically significant and unbiased (Egger&#x02019;s test: P=0.095).</p></sec><sec id="s3_5_6"><title>Vomiting</title><p>A meta-analysis was conducted on eight articles reporting the incidence of vomiting. These articles had mild heterogeneity (I<sup>2</sup> = 38%, P=0.12). Random effects were used to merge the effects, and we found that the results were not statistically significant (RR=0.71, P=0.07). Therefore, the addition of <italic>S. boulardii</italic> did not reduce the incidence of vomiting.</p></sec><sec id="s3_5_7"><title>Taste disorders</title><p>We conducted a meta-analysis on seven articles that studied the incidence of taste disorders and found moderate heterogeneity (I<sup>2</sup> = 64%, P=0.01). Random effects were used to merge the effects, and the results were not statistically significant (RR=0.82, P=0.4). Therefore, the addition of <italic>S. boulardii</italic> did not reduce the incidence of taste disorders (<xref rid="T3" ref-type="table">
<bold>Table 3</bold>
</xref>).</p><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Incidence rate of other adverse reactions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Adverse reactions</th><th valign="middle" align="center" rowspan="1" colspan="1">Number of Articles</th><th valign="middle" align="center" rowspan="1" colspan="1">Sample size</th><th valign="middle" align="center" rowspan="1" colspan="1">RR (95%)</th><th valign="middle" align="center" rowspan="1" colspan="1">P</th><th valign="middle" align="center" rowspan="1" colspan="1">I<sup>2</sup>(%)</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">diarrhea</td><td valign="middle" align="center" rowspan="1" colspan="1">16</td><td valign="middle" align="center" rowspan="1" colspan="1">3701</td><td valign="middle" align="center" rowspan="1" colspan="1">0.36 (0.26-0.48)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.00001</td><td valign="middle" align="center" rowspan="1" colspan="1">58</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">abdominal pain</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">2153</td><td valign="middle" align="center" rowspan="1" colspan="1">0.78 (0.57-1.05)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.1</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">abdominal distension</td><td valign="middle" align="center" rowspan="1" colspan="1">7</td><td valign="middle" align="center" rowspan="1" colspan="1">1308</td><td valign="middle" align="center" rowspan="1" colspan="1">0.49 (0.33-0.72)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0004</td><td valign="middle" align="center" rowspan="1" colspan="1">43</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">constipation</td><td valign="middle" align="center" rowspan="1" colspan="1">6</td><td valign="middle" align="center" rowspan="1" colspan="1">1324</td><td valign="middle" align="center" rowspan="1" colspan="1">0.38 (0.26-0.57)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.00001</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">nausea</td><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="center" rowspan="1" colspan="1">2505</td><td valign="middle" align="center" rowspan="1" colspan="1">0.50 (0.37-0.68)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.00001</td><td valign="middle" align="center" rowspan="1" colspan="1">48</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">vomit</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">1744</td><td valign="middle" align="center" rowspan="1" colspan="1">0.71 (0.50-1.02)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.07</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">taste disorders</td><td valign="middle" align="center" rowspan="1" colspan="1">7</td><td valign="middle" align="center" rowspan="1" colspan="1">1417</td><td valign="middle" align="center" rowspan="1" colspan="1">0.82 (0.51-1.31)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.4</td><td valign="middle" align="center" rowspan="1" colspan="1">64</td></tr></tbody></table><table-wrap-foot><fn><p>Effect of <italic>S. boulardii</italic> as an adjuvant therapy for <italic>H. pylori</italic> on adverse effects. RR, relative risk; P, probability.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this meta-analysis, we investigated changes in the rates of <italic>H. pylori</italic> eradication after the addition of <italic>S. boulardii</italic> to eradication therapy using ITT analysis. In the ITT analysis, we found that the addition of <italic>S. boulardii</italic> increased the eradication rate by 11%, with statistically significant and non-heterogeneous results consistent with those of a previous meta-analysis published by Zhou et&#x000a0;al. in 2019 (<xref rid="B38" ref-type="bibr">Zhou et&#x000a0;al., 2019</xref>). In the two latest RCTs published in 2022&#x02014;one of which was a triple-protocol study by Yang et&#x000a0;al (<xref rid="B34" ref-type="bibr">Yang et&#x000a0;al., 2022</xref>).including 497 patients&#x02014;the eradication rate increased by 12.6% after the addition of <italic>S. boulardii</italic>, which is consistent with our results. Another RCT performed by <xref rid="B22" ref-type="bibr">Naghibzadeh et&#x000a0;al. (2022)</xref> found that the addition of <italic>S. boulardii</italic> increased the eradication rate by 7.7% in 156 patients undergoing quadruple therapy; however, this increase was not statistically significant. This might have been due to various factors such as the inclusion of a placebo in the experiment, the fact that quadruple therapy itself improved the eradication effect compared to triple therapy, or an insufficient dosage of <italic>S. boulardii</italic>.</p><p>When we studied the total adverse effects reported by the included studies, we found a high degree of heterogeneity in their results. Further investigation of L&#x02019;Abb&#x000e9; and radial plots confirmed this high degree of heterogeneity. Upon conducting a sensitivity analysis of these studies, we found that deleting any articles did not cause a significant change in the results. Additionally, the sensitivity analysis did not identify the source of heterogeneity. Therefore, we conducted a subgroup analysis from multiple dimensions; however, we did not find any sources of heterogeneity, indicating a reliable 51% reduction in total adverse effects. This conclusion is consistent with the results of a previous meta-analysis by Zhou et&#x000a0;al (<xref rid="B38" ref-type="bibr">Zhou et&#x000a0;al., 2019</xref>), showing that the addition of <italic>S. boulardii</italic> can reduce the total adverse effects of eradication therapy.</p><p>When studying the incidence of diarrhea, we examined the L&#x02019;Abb&#x000e9; and radial plots again and found moderate heterogeneity. A sensitivity analysis was conducted on these studies, and it was found that the study by <xref rid="B28" ref-type="bibr">Seddik et&#x000a0;al. (2019)</xref> had a significant impact on heterogeneity. After excluding this study, the I<sup>2</sup> decreased to &#x0003c;50%. This study was the only treatment that used sequential therapy; therefore, we concluded that this study might have been a source of heterogeneity. Owing to antibiotic resistance and the adverse effects of bismuth, sequential therapy can serve as a replacement for traditional triple or quadruple therapy failures (<xref rid="B35" ref-type="bibr">Yang et&#x000a0;al., 2014</xref>). A study by <xref rid="B42" ref-type="bibr">Zullo et&#x000a0;al. (2003)</xref> including 1,749 patients showed that sequential therapy had a higher eradication rate than traditional therapy (92% vs. 74%). Therefore, sequential therapy may become a new-generation first-line treatment option in the future; however, further experimental studies are required to confirm its efficacy and safety.</p><p>In this meta-analysis, we concluded that the addition of <italic>S. boulardii</italic> to eradication therapy significantly reduced the incidence of abdominal distension, constipation, and nausea, with no heterogeneity or only mild heterogeneity. Similarly, a recent triple-protocol RCT in China (<xref rid="B34" ref-type="bibr">Yang et&#x000a0;al., 2022</xref>) showed a significant improvement in abdominal distension with <italic>S. boulardii</italic> supplementation. Our findings are also consistent with the results of a previous meta-analysis by <xref rid="B38" ref-type="bibr">Zhou et&#x000a0;al. (2019)</xref> that investigated the incidence of diarrhea, bloating, constipation, and nausea with eradication therapy. These results confirm that the addition of <italic>S. boulardii</italic> can reduce the occurrence of these adverse reactions, providing a theoretical basis for clinical practice.</p><p>After conducting a stratified analysis of 18 articles, we found that the eradication rate in the child group increased by 5% when compared with that in the adult group. This is consistent with Zhou et&#x000a0;al.&#x02019;s (<xref rid="B38" ref-type="bibr">Zhou et&#x000a0;al., 2019</xref>) finding that the eradication rate in children increased by 3.25% when compared with that in adults. Additionally, we found that the eradication rate of quadruple therapy was higher than that of triple therapy, with an increase of 7%. However, sequential therapy had the highest eradication rate, with an increase of 9% when compared with quadruple therapy. Notably, sequential therapy has several advantages over traditional therapy, with some studies reporting that sequential therapy can increase the eradication rate by 18% when compared with traditional therapy (<xref rid="B42" ref-type="bibr">Zullo et&#x000a0;al., 2003</xref>). This presents new possibilities for clinical treatment. In this study, we also compared the eradication rates at different study locations and medication durations; however, we found no significant differences in these factors.</p><p>The present meta-analysis evaluated the incidence of other adverse effects such as abdominal pain, vomiting, and taste disorders. Although the incidence of these adverse effects decreased with the addition of <italic>S. boulardii</italic>, these results were not statistically significant. Consistent with our results, <xref rid="B22" ref-type="bibr">Naghibzadeh et&#x000a0;al. (2022)</xref> found no significant improvement in the incidence of vomiting and taste disorders with the addition of <italic>S. boulardii</italic>. Since there is currently limited clinical research regarding whether the addition of <italic>S. boulardii</italic> can decrease these adverse effects, these results may still hold some significance for clinical practice. However, further studies are required to confirm this hypothesis.</p><p>Previous studies have also shown that other probiotics may increase the eradication rate of <italic>H. pylori</italic> and reduce adverse effects. For example, <xref rid="B22" ref-type="bibr">Naghibzadeh et&#x000a0;al. (2022)</xref> studied a group of treatment regimens using <italic>L. reuteri</italic> in combination with quadruple therapy and found a small improvement in the eradication rate; however, these results were not statistically significant. Similarly, <xref rid="B40" ref-type="bibr">Zhu et&#x000a0;al. (2018)</xref> studied a treatment regimen using <italic>L. reuteri</italic> and found a 2.5% increase in the eradication rate, which was also not statistically significant. Previous research has shown that the colonization of lactobacilli in the stomach can reduce the production of gastritis, promote mucus regeneration, downregulate the expression of cag pathogenicity island genes (<xref rid="B11" ref-type="bibr">Garc&#x000ed;a et&#x000a0;al., 2012</xref>), and prevent the colonization of <italic>H. pylori</italic> through specific adhesives. Another prospective trial statistically analyzed the efficacy of combining four probiotics (<italic>Lactobacillus acidophilus</italic>, <italic>Lactiplantacillus plantarum</italic>, <italic>Bifidobacterium lactis</italic>, and <italic>S. boulardii</italic>) and found that combining multiple probiotics can improve eradication rates and reduce the incidence of adverse effects (<xref rid="B32" ref-type="bibr">Viazis et&#x000a0;al., 2022</xref>). However, further randomized trials are required to confirm the efficacy of these probiotics.</p><p>Previous researchers have also studied patients&#x02019; compliance with the addition of <italic>S. boulardii</italic> to <italic>H. pylori</italic> eradication therapy. <xref rid="B28" ref-type="bibr">Seddik et&#x000a0;al. (2019)</xref> found that adding <italic>S. boulardii</italic> to the sequential treatment increased treatment compliance by 3.8% (95.0% vs. 91.2%, P&#x0003c;0.001). Similarly, in an RCT involving children, <xref rid="B1" ref-type="bibr">Bin et&#x000a0;al. (2015)</xref> found that no patient in the treatment group terminated <italic>H. pylori</italic> treatment prematurely, whereas six patients in the control group stopped treatment without medical advice, with a statistically significant difference (p=0.027). However, due to the small sample size of their study, further investigation is required to determine whether <italic>S. boulardii</italic> can improve patient compliance with eradication therapy.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>We found that adding <italic>S. boulardii</italic> to traditional eradication treatment methods can improve the <italic>H. pylori</italic> eradication rate and reduce the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea. However, it did not reduce the incidence of abdominal pain, vomiting, and taste disorders.</p></sec></body><back><ack><title>Acknowledgments</title><p>In the process of writing this meta-analysis, we acknowledge everyone who provided a lot of help in the structure and writing standards of the article.</p></ack><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author/s.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>ML: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. YX: Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bin</surname><given-names>Z.</given-names></name>
<name><surname>Ya-Zheng</surname><given-names>X.</given-names></name>
<name><surname>Zhao-Hui</surname><given-names>D.</given-names></name>
<name><surname>Bo</surname><given-names>C.</given-names></name>
<name><surname>Li-Rong</surname><given-names>J.</given-names></name>
<name><surname>Vandenplas</surname><given-names>Y.</given-names></name>
</person-group> (<year>2015</year>). <article-title>The Efficacy of Saccharomyces boulardii CNCM I-745 in Addition to Standard Helicobacter pylori Eradication Treatment in Children</article-title>. <source>Pediatr. Gastroenterol. Hepatol. Nutr.</source>
<volume>18</volume>, <fpage>17</fpage>&#x02013;<lpage>22</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.5223/pghn.2015.18.1.17</pub-id>
<pub-id pub-id-type="pmid">25866729</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Buts</surname><given-names>J. P.</given-names></name>
<name><surname>Bernasconi</surname><given-names>P.</given-names></name>
<name><surname>Vaerman</surname><given-names>J. P.</given-names></name>
<name><surname>Dive</surname><given-names>C.</given-names></name>
</person-group> (<year>1990</year>). <article-title>Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces Boulardii</article-title>. <source>Dig Dis. Sci.</source>
<volume>35</volume>, <fpage>251</fpage>&#x02013;<lpage>256</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/BF01536771</pub-id>
<pub-id pub-id-type="pmid">2302983</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>Y. W.</given-names></name>
<name><surname>Park</surname><given-names>Y. M.</given-names></name>
<name><surname>Oh</surname><given-names>C. H.</given-names></name>
<name><surname>Oh</surname><given-names>S. J.</given-names></name>
<name><surname>Cho</surname><given-names>J. H.</given-names></name>
<name><surname>Kim</surname><given-names>J. W.</given-names></name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy</article-title>. <source>Korean J. Intern. Med.</source>
<volume>35</volume>, <fpage>574</fpage>&#x02013;<lpage>581</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3904/kjim.2019.139</pub-id>
<pub-id pub-id-type="pmid">31830776</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chotivitayatarakorn</surname><given-names>P.</given-names></name>
<name><surname>Mahachai</surname><given-names>V.</given-names></name>
<name><surname>Vilaichone</surname><given-names>R. K.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Effectiveness of 7-day and 14-day moxifloxacin-dexlansoprazole based triple therapy and probiotic supplement for helicobacter pylori eradication in Thai patients with non-ulcer dyspepsia: A double-blind randomized placebo-controlled study</article-title>. <source>Asian Pac J. Cancer Prev.</source>
<volume>18</volume>, <fpage>2839</fpage>&#x02013;<lpage>2843</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.22034/apjcp.2017.18.10.2839</pub-id>
<pub-id pub-id-type="pmid">29072432</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cifuentes</surname><given-names>S. G.</given-names></name>
<name><surname>Prado</surname><given-names>M. B.</given-names></name>
<name><surname>Fornasini</surname><given-names>M.</given-names></name>
<name><surname>Cohen</surname><given-names>H.</given-names></name>
<name><surname>Balde&#x000f3;n</surname><given-names>M. E.</given-names></name>
<name><surname>C&#x000e1;rdenas</surname><given-names>P. A.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy</article-title>. <source>Helicobacter</source>
<volume>27</volume>, <elocation-id>e12870</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/hel.12870</pub-id>
<pub-id pub-id-type="pmid">34990038</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cindoruk</surname><given-names>M.</given-names></name>
<name><surname>Erkan</surname><given-names>G.</given-names></name>
<name><surname>Karakan</surname><given-names>T.</given-names></name>
<name><surname>Dursun</surname><given-names>A.</given-names></name>
<name><surname>Unal</surname><given-names>S.</given-names></name>
</person-group> (<year>2007</year>). <article-title>Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study</article-title>. <source>Helicobacter</source>
<volume>12</volume>, <fpage>309</fpage>&#x02013;<lpage>316</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1523-5378.2007.00516.x</pub-id>
<pub-id pub-id-type="pmid">17669103</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cremonini</surname><given-names>F.</given-names></name>
<name><surname>Di Caro</surname><given-names>S.</given-names></name>
<name><surname>Covino</surname><given-names>M.</given-names></name>
<name><surname>Armuzzi</surname><given-names>A.</given-names></name>
<name><surname>Gabrielli</surname><given-names>M.</given-names></name>
<name><surname>Santarelli</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>). <article-title>Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study</article-title>. <source>Am. J. Gastroenterol.</source>
<volume>97</volume>, <fpage>2744</fpage>&#x02013;<lpage>2749</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1572-0241.2002.07063.x</pub-id>
<pub-id pub-id-type="pmid">12425542</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dahan</surname><given-names>S.</given-names></name>
<name><surname>Dalmasso</surname><given-names>G.</given-names></name>
<name><surname>Imbert</surname><given-names>V.</given-names></name>
<name><surname>Peyron</surname><given-names>J. F.</given-names></name>
<name><surname>Rampal</surname><given-names>P.</given-names></name>
<name><surname>Czerucka</surname><given-names>D.</given-names></name>
</person-group> (<year>2003</year>). <article-title>Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells</article-title>. <source>Infect. Immun.</source>
<volume>71</volume>, <fpage>766</fpage>&#x02013;<lpage>773</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/IAI.71.2.766-773.2003</pub-id>
<pub-id pub-id-type="pmid">12540556</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Duman</surname><given-names>D. G.</given-names></name>
<name><surname>Bor</surname><given-names>S.</given-names></name>
<name><surname>Oz&#x000fc;temiz</surname><given-names>O.</given-names></name>
<name><surname>Sahin</surname><given-names>T.</given-names></name>
<name><surname>O&#x0011f;uz</surname><given-names>D.</given-names></name>
<name><surname>I&#x0015f;tan</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication</article-title>. <source>Eur. J. Gastroenterol. Hepatol.</source>
<volume>17</volume>, <fpage>1357</fpage>&#x02013;<lpage>1361</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/00042737-200512000-00015</pub-id>
<pub-id pub-id-type="pmid">16292090</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Flores-Trevi&#x000f1;o</surname><given-names>S.</given-names></name>
<name><surname>Mendoza-Olazar&#x000e1;n</surname><given-names>S.</given-names></name>
<name><surname>Bocanegra-Ibarias</surname><given-names>P.</given-names></name>
<name><surname>Maldonado-Garza</surname><given-names>H. J.</given-names></name>
<name><surname>Garza-Gonz&#x000e1;lez</surname><given-names>E.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Helicobacter pylori drug resistance: therapy changes and challenges</article-title>. <source>Expert Rev. Gastroenterol. Hepatol.</source>
<volume>12</volume>, <fpage>819</fpage>&#x02013;<lpage>827</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/17474124.2018.1496017</pub-id>
<pub-id pub-id-type="pmid">29976092</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Garc&#x000ed;a</surname><given-names>A.</given-names></name>
<name><surname>S&#x000e1;ez</surname><given-names>K.</given-names></name>
<name><surname>Delgado</surname><given-names>C.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>C. L.</given-names></name>
</person-group> (<year>2012</year>). <article-title>Low co-existence rates of Lactobacillus spp. and Helicobacter pylori detected in gastric biopsies from patients with gastrointestinal symptoms</article-title>. <source>Rev. Esp Enferm Dig</source>
<volume>104</volume>, <fpage>473</fpage>&#x02013;<lpage>478</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4321/s1130-01082012000900005</pub-id>
<pub-id pub-id-type="pmid">23130855</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>He</surname><given-names>C. X.</given-names></name>
<name><surname>Kong</surname><given-names>F. T.</given-names></name>
<name><surname>Liang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>K. X.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Y. L.</given-names></name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>
<volume>99</volume>, <fpage>1731</fpage>&#x02013;<lpage>1734</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3760/cma.j.issn.0376-2491.2019.22.010</pub-id>
<pub-id pub-id-type="pmid">31216821</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>He</surname><given-names>J. e.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Saccharomyces boulardii combined with triple therapy in treatment of Helicobacter pylori infection in children: A clinical observation</article-title>. <source>Chin. J. Microecology</source>
<volume>31</volume>, <fpage>171</fpage>&#x02013;<lpage>173,178</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.13381/j.cnki.cjm.201902011</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Helicobacter pylori Study Group, C. S. o. G</collab>
<collab>Chinese Medical Association</collab>
</person-group> (<year>2022</year>). <article-title>Sixth Chinese National Consensus report on management of <italic>Helicobacter pylori</italic> infection (treatment rxcluded)</article-title>. <source>Chin J Gastroenterol</source>. <volume>27</volume>, <fpage>289</fpage>&#x02013;<lpage>304</lpage>.</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hurduc</surname><given-names>V.</given-names></name>
<name><surname>Plesca</surname><given-names>D.</given-names></name>
<name><surname>Dragomir</surname><given-names>D.</given-names></name>
<name><surname>Sajin</surname><given-names>M.</given-names></name>
<name><surname>Vandenplas</surname><given-names>Y.</given-names></name>
</person-group> (<year>2009</year>). <article-title>A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children</article-title>. <source>Acta Paediatr.</source>
<volume>98</volume>, <fpage>127</fpage>&#x02013;<lpage>131</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1651-2227.2008.00977.x</pub-id>
<pub-id pub-id-type="pmid">18681892</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Katelaris</surname><given-names>P.</given-names></name>
<name><surname>Hunt</surname><given-names>R.</given-names></name>
<name><surname>Bazzoli</surname><given-names>F.</given-names></name>
<name><surname>Cohen</surname><given-names>H.</given-names></name>
<name><surname>Fock</surname><given-names>K. M.</given-names></name>
<name><surname>Gemilyan</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Helicobacter pylori world gastroenterology organization global guideline</article-title>. <source>J. Clin. Gastroenterol.</source>
<volume>57</volume>, <fpage>111</fpage>&#x02013;<lpage>126</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/mcg.0000000000001719</pub-id>
<pub-id pub-id-type="pmid">36598803</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ka&#x0017a;mierczak-Siedlecka</surname><given-names>K.</given-names></name>
<name><surname>Ruszkowski</surname><given-names>J.</given-names></name>
<name><surname>Fic</surname><given-names>M.</given-names></name>
<name><surname>Folwarski</surname><given-names>M.</given-names></name>
<name><surname>Makarewicz</surname><given-names>W.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Saccharomyces boulardii CNCM I-745: A non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases</article-title>. <source>Curr. Microbiol.</source>
<volume>77</volume>, <fpage>1987</fpage>&#x02013;<lpage>1996</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00284-020-02053-9</pub-id>
<pub-id pub-id-type="pmid">32472262</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lazo-V&#x000e9;lez</surname><given-names>M. A.</given-names></name>
<name><surname>Serna-Sald&#x000ed;var</surname><given-names>S. O.</given-names></name>
<name><surname>Rosales-Medina</surname><given-names>M. F.</given-names></name>
<name><surname>Tinoco-Alvear</surname><given-names>M.</given-names></name>
<name><surname>Briones-Garc&#x000ed;a</surname><given-names>M.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Application of Saccharomyces cerevisiae var. boulardii in food processing: a review</article-title>. <source>J. Appl. Microbiol.</source>
<volume>125</volume>, <fpage>943</fpage>&#x02013;<lpage>951</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jam.14037</pub-id>
<pub-id pub-id-type="pmid">29961970</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Malfertheiner</surname><given-names>P.</given-names></name>
<name><surname>Megraud</surname><given-names>F.</given-names></name>
<name><surname>O&#x02019;Morain</surname><given-names>C. A.</given-names></name>
<name><surname>Atherton</surname><given-names>J.</given-names></name>
<name><surname>Axon</surname><given-names>A. T.</given-names></name>
<name><surname>Bazzoli</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Management of Helicobacter pylori infection&#x02013;the Maastricht IV/Florence Consensus Report</article-title>. <source>Gut</source>
<volume>61</volume>, <fpage>646</fpage>&#x02013;<lpage>664</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/gutjnl-2012-302084</pub-id>
<pub-id pub-id-type="pmid">22491499</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McFarland</surname><given-names>L. V.</given-names></name>
</person-group> (<year>2010</year>). <article-title>Systematic review and meta-analysis of Saccharomyces boulardii in adult patients</article-title>. <source>World J. Gastroenterol.</source>
<volume>16</volume>, <fpage>2202</fpage>&#x02013;<lpage>2222</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3748/wjg.v16.i18.2202</pub-id>
<pub-id pub-id-type="pmid">20458757</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mesquita</surname><given-names>A.</given-names></name>
<name><surname>Rocha-Castro</surname><given-names>C.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>D.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Soutinho</surname><given-names>J.</given-names></name>
<name><surname>Taveira-Gomes</surname><given-names>T.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Multicentric study to assess helicobacter pylori incidence, patient reported adverse events, compliance and effectiveness, in real-world setting</article-title>. <source>Int. J. Environ. Res. Public Health</source>
<volume>19</volume>, <fpage>2</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijerph191912847</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Naghibzadeh</surname><given-names>N.</given-names></name>
<name><surname>Salmani</surname><given-names>F.</given-names></name>
<name><surname>Nomiri</surname><given-names>S.</given-names></name>
<name><surname>Tavakoli</surname><given-names>T.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial</article-title>. <source>BMC Gastroenterol.</source>
<volume>22</volume>, <fpage>107</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12876-022-02187-z</pub-id>
<pub-id pub-id-type="pmid">35255819</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Namkin</surname><given-names>K.</given-names></name>
<name><surname>Zardast</surname><given-names>M.</given-names></name>
<name><surname>Basirinejad</surname><given-names>F.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Saccharomyces boulardii in helicobacter pylori eradication in children: A randomized trial from Iran</article-title>. <source>Iran J. Pediatr.</source>
<volume>26</volume>, <fpage>e3768</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.5812/ijp.3768</pub-id>
<pub-id pub-id-type="pmid">26848376</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pais</surname><given-names>P.</given-names></name>
<name><surname>Almeida</surname><given-names>V.</given-names></name>
<name><surname>Y&#x00131;lmaz</surname><given-names>M.</given-names></name>
<name><surname>Teixeira</surname><given-names>M. C.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Saccharomyces boulardii: what makes it tick as successful probiotic</article-title>? <source>J. Fungi (Basel)</source>
<volume>6</volume>, <fpage>2</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/jof6020078</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Peek</surname><given-names>R. M.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Introduction. Helicobacter pylori</article-title>. <source>Gut Microbes</source>
<volume>4</volume>, <fpage>425</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4161/gmic.27169</pub-id>
<pub-id pub-id-type="pmid">24262863</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ren</surname><given-names>S.</given-names></name>
<name><surname>Cai</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis</article-title>. <source>J. Gastroenterol. Hepatol.</source>
<volume>37</volume>, <fpage>464</fpage>&#x02013;<lpage>470</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jgh.15751</pub-id>
<pub-id pub-id-type="pmid">34862656</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sakarya</surname><given-names>S.</given-names></name>
<name><surname>Gunay</surname><given-names>N.</given-names></name>
</person-group> (<year>2014</year>). <article-title>Saccharomyces boulardii expresses neuraminidase activity selective for &#x003b1;2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells</article-title>. <source>Apmis</source>
<volume>122</volume>, <fpage>941</fpage>&#x02013;<lpage>950</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/apm.12237</pub-id>
<pub-id pub-id-type="pmid">24628732</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Seddik</surname><given-names>H.</given-names></name>
<name><surname>Boutallaka</surname><given-names>H.</given-names></name>
<name><surname>Elkoti</surname><given-names>I.</given-names></name>
<name><surname>Nejjari</surname><given-names>F.</given-names></name>
<name><surname>Berraida</surname><given-names>R.</given-names></name>
<name><surname>Berrag</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial</article-title>. <source>Eur. J. Clin. Pharmacol.</source>
<volume>75</volume>, <fpage>639</fpage>&#x02013;<lpage>645</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00228-019-02625-0</pub-id>
<pub-id pub-id-type="pmid">30694338</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>M. J.</given-names></name>
<name><surname>Park</surname><given-names>D. I.</given-names></name>
<name><surname>Park</surname><given-names>J. H.</given-names></name>
<name><surname>Kim</surname><given-names>H. J.</given-names></name>
<name><surname>Cho</surname><given-names>Y. K.</given-names></name>
<name><surname>Sohn</surname><given-names>C. I.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori</article-title>. <source>Helicobacter</source>
<volume>15</volume>, <fpage>206</fpage>&#x02013;<lpage>213</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1523-5378.2010.00751.x</pub-id>
<pub-id pub-id-type="pmid">20557362</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Helicobacter pylori recrudescence and its influencing factors</article-title>. <source>J. Cell Mol. Med.</source>
<volume>23</volume>, <fpage>7919</fpage>&#x02013;<lpage>7925</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jcmm.14682</pub-id>
<pub-id pub-id-type="pmid">31536675</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Szajewska</surname><given-names>H.</given-names></name>
<name><surname>Horvath</surname><given-names>A.</given-names></name>
<name><surname>Ko&#x00142;odziej</surname><given-names>M.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection</article-title>. <source>Aliment Pharmacol. Ther.</source>
<volume>41</volume>, <fpage>1237</fpage>&#x02013;<lpage>1245</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/apt.13214</pub-id>
<pub-id pub-id-type="pmid">25898944</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Viazis</surname><given-names>N.</given-names></name>
<name><surname>Argyriou</surname><given-names>K.</given-names></name>
<name><surname>Kotzampassi</surname><given-names>K.</given-names></name>
<name><surname>Christodoulou</surname><given-names>D. K.</given-names></name>
<name><surname>Apostolopoulos</surname><given-names>P.</given-names></name>
<name><surname>Georgopoulos</surname><given-names>S. D.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>A four-probiotics regimen combined with A standard helicobacter pylori-eradication treatment reduces side effects and increases eradication rates</article-title>. <source>Nutrients</source>
<volume>14</volume>, <fpage>8</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/nu14030632</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Effectiveness of different courses of Saccharomyces boulardii therapy in Helicobacter pylori eradication</article-title>. <source>Chin. J. Microecology</source>
<volume>27</volume>, <fpage>55</fpage>&#x02013;<lpage>59</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.13381/j.cnki.cjm.201501014</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>G. B.</given-names></name>
<name><surname>Hu</surname><given-names>F. L.</given-names></name>
<name><surname>Cheng</surname><given-names>W.</given-names></name>
<name><surname>Gao</surname><given-names>J. Q.</given-names></name>
<name><surname>Sheng</surname><given-names>Z. Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y. J.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>A multi-center, randomized controlled study on the effect of Saccharomyces boulardii combined with triple therapy for the initial eradication of Helicobacter pylori infection</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>
<volume>102</volume>, <fpage>1383</fpage>&#x02013;<lpage>1388</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3760/cma.j.cn112137-20210811-01790</pub-id>
<pub-id pub-id-type="pmid">35545584</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J. C.</given-names></name>
<name><surname>Lu</surname><given-names>C. W.</given-names></name>
<name><surname>Lin</surname><given-names>C. J.</given-names></name>
</person-group> (<year>2014</year>). <article-title>Treatment of Helicobacter pylori infection: current status and future concepts</article-title>. <source>World J. Gastroenterol.</source>
<volume>20</volume>, <fpage>5283</fpage>&#x02013;<lpage>5293</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3748/wjg.v20.i18.5283</pub-id>
<pub-id pub-id-type="pmid">24833858</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H. M.</given-names></name>
<name><surname>Ou-Yang</surname><given-names>H. J.</given-names></name>
<name><surname>Duan</surname><given-names>B. P.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>Z. Y.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>
<volume>16</volume>, <fpage>230</fpage>&#x02013;<lpage>233</lpage>.<pub-id pub-id-type="pmid">24661511</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Aruna</surname></name>
<name><surname>Xiao</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial</article-title>. <source>Front. Med. (Lausanne)</source>
<volume>8</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmed.2021.776955</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>B. G.</given-names></name>
<name><surname>Chen</surname><given-names>L. X.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Wan</surname><given-names>L. Y.</given-names></name>
<name><surname>Ai</surname><given-names>Y. W.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis</article-title>. <source>Helicobacter</source>
<volume>24</volume>, <elocation-id>e12651</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/hel.12651</pub-id>
<pub-id pub-id-type="pmid">31414551</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>X. Y.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>L. W.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>G. F.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Influence of Saccharomyces boulardii Sachets combined with bismuth quadruple therapy for initial Helicobacter pylori eradication</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>
<volume>97</volume>, <fpage>2353</fpage>&#x02013;<lpage>2356</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3760/cma.j.issn.0376-2491.2017.30.008</pub-id>
<pub-id pub-id-type="pmid">28822453</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>X. Y.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>W. J.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>L. W.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Influence of two kinds of probiotics combined with bismuth quadruple therapy for Helicobacter pylori eradication</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>
<volume>98</volume>, <fpage>2246</fpage>&#x02013;<lpage>2249</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3760/cma.j.issn.0376-2491.2018.28.007</pub-id>
<pub-id pub-id-type="pmid">30078279</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zojaji</surname><given-names>H.</given-names></name>
<name><surname>Ghobakhlou</surname><given-names>M.</given-names></name>
<name><surname>Rajabalinia</surname><given-names>H.</given-names></name>
<name><surname>Ataei</surname><given-names>E.</given-names></name>
<name><surname>Jahani Sherafat</surname><given-names>S.</given-names></name>
<name><surname>Moghimi-Dehkordi</surname><given-names>B.</given-names></name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trial</article-title>. <source>Gastroenterol. Hepatol. Bed Bench</source>
<volume>6</volume>, <fpage>S99</fpage>&#x02013;<lpage>s104</lpage>.<pub-id pub-id-type="pmid">24834296</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zullo</surname><given-names>A.</given-names></name>
<name><surname>Vaira</surname><given-names>D.</given-names></name>
<name><surname>Vakil</surname><given-names>N.</given-names></name>
<name><surname>Hassan</surname><given-names>C.</given-names></name>
<name><surname>Gatta</surname><given-names>L.</given-names></name>
<name><surname>Ricci</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>High eradication rates of Helicobacter pylori with a new sequential treatment</article-title>. <source>Aliment Pharmacol. Ther.</source>
<volume>17</volume>, <fpage>719</fpage>&#x02013;<lpage>726</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01461.x</pub-id>
<pub-id pub-id-type="pmid">12641522</pub-id>
</mixed-citation></ref></ref-list></back></article>